DURVALUMAB for Transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 69 adverse event reports in the FDA FAERS database where DURVALUMAB was used for Transitional cell carcinoma.
Most Reported Side Effects for DURVALUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 2,817 | 16.4% | 2,816 | 98 |
| Malignant neoplasm progression | 1,330 | 7.8% | 343 | 166 |
| Pneumonitis | 827 | 4.8% | 221 | 333 |
| Radiation pneumonitis | 786 | 4.6% | 112 | 343 |
| Pyrexia | 573 | 3.3% | 79 | 372 |
| Diarrhoea | 530 | 3.1% | 99 | 267 |
| Pneumonia | 453 | 2.6% | 169 | 300 |
| Dyspnoea | 444 | 2.6% | 113 | 215 |
| Interstitial lung disease | 430 | 2.5% | 144 | 220 |
| Off label use | 395 | 2.3% | 70 | 102 |
| Fatigue | 367 | 2.1% | 57 | 102 |
| Rash | 359 | 2.1% | 43 | 94 |
| Neutrophil count decreased | 343 | 2.0% | 49 | 76 |
| Asthenia | 326 | 1.9% | 104 | 121 |
| Colitis | 319 | 1.9% | 73 | 164 |
Other Indications for DURVALUMAB
Non-small cell lung cancer (3,396)
Hepatocellular carcinoma (1,255)
Small cell lung cancer (1,063)
Bile duct cancer (972)
Non-small cell lung cancer stage iii (840)
Small cell lung cancer extensive stage (660)
Lung neoplasm malignant (641)
Pancreatic carcinoma (584)
Cholangiocarcinoma (444)
Neoplasm malignant (253)
Other Drugs Used for Transitional cell carcinoma
PEMBROLIZUMAB (1,951)
ENFORTUMAB VEDOTIN-EJFV (1,179)
GEMCITABINE (825)
ATEZOLIZUMAB (788)
CISPLATIN (672)
ENFORTUMAB VEDOTIN (649)
NIVOLUMAB (595)
AVELUMAB (554)
CARBOPLATIN (493)
GEMCITABINE\GEMCITABINE (255)